000302169 001__ 302169
000302169 005__ 20250629021231.0
000302169 0247_ $$2doi$$a10.1136/bmjonc-2025-000783
000302169 0247_ $$2pmid$$apmid:40546927
000302169 0247_ $$2pmc$$apmc:PMC12182000
000302169 0247_ $$2altmetric$$aaltmetric:178162555
000302169 037__ $$aDKFZ-2025-01287
000302169 041__ $$aEnglish
000302169 082__ $$a610
000302169 1001_ $$aPuccini, Alberto$$b0
000302169 245__ $$aPatient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM).
000302169 260__ $$a[London]$$bBMJ Publishing$$c2025
000302169 3367_ $$2DRIVER$$aarticle
000302169 3367_ $$2DataCite$$aOutput Types/Journal article
000302169 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1750916712_330
000302169 3367_ $$2BibTeX$$aARTICLE
000302169 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302169 3367_ $$00$$2EndNote$$aJournal Article
000302169 520__ $$aPatient-reported outcomes (PROs) are considered the gold standard for the assessment of subjective symptoms, quality of life (QoL) and patient well-being in both clinical trials and clinical practice. Here, we report key discussions and findings from the 21st National Conference of the Italian Association of Medical Oncology, held in Bologna on 21-22 June 2024, with a focus on the integration and impact of PROs in oncology research and clinical practice.Leading national and international experts presented and analysed data regarding the use of PROs in clinical trials and routine oncology care. Topics included the role of electronic PROs (ePROs), digital therapeutics, financial toxicity as a PRO and methodologies for standardising QoL assessment. Insights were drawn from expert presentations, consensus discussions and practical experiences shared during the conference sessions.Experts emphasised that PROs should be included as key endpoints in clinical trials, with timely publication of results and standardised methodologies for analysis and interpretation. The conference highlighted the critical importance of incorporating PROs and QoL measures throughout the cancer care continuum-from screening to survivorship. In clinical practice, PROs improve patient-centred care and communication, particularly when oncologists are trained to interpret QoL data. The use of ePROs was noted as a valuable tool to support digital health interventions. Financial toxicity emerged as a significant PRO, with screening tools recommended to identify and support at-risk patients. Key organisational challenges were identified, including technological barriers, resource constraints and the need for responsive infrastructure to support real-time PRO integration.The implementation of PROs, including ePROs and financial toxicity assessments, is essential for advancing quality cancer care. Standardisation, digital innovation and targeted clinician education are critical to integrating PROs effectively in both research and clinical settings. Addressing infrastructural and technological challenges will be vital for optimising patient outcomes and ensuring optimal care across the cancer journey.
000302169 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000302169 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302169 650_7 $$2Other$$aAdverse effects
000302169 650_7 $$2Other$$aClinical Trial
000302169 650_7 $$2Other$$aPatient Safety
000302169 650_7 $$2Other$$aPsycho-oncology
000302169 7001_ $$aViscardi, Giuseppe$$b1
000302169 7001_ $$aCiani, Oriana$$b2
000302169 7001_ $$aEfficace, Fabio$$b3
000302169 7001_ $$aPiattelli, Angela$$b4
000302169 7001_ $$aBeretta, Giordano Domenico$$b5
000302169 7001_ $$aPetruzzelli, Davide$$b6
000302169 7001_ $$aPopoli, Patrizia$$b7
000302169 7001_ $$aDe Lorenzo, Francesco$$b8
000302169 7001_ $$aLongo, Francesco$$b9
000302169 7001_ $$aZibellini, Marco$$b10
000302169 7001_ $$aGitto, Lara$$b11
000302169 7001_ $$aBrunello, Antonella$$b12
000302169 7001_ $$aMaiello, Evaristo$$b13
000302169 7001_ $$00000-0003-3624-224X$$aServetto, Alberto$$b14
000302169 7001_ $$aPagliuca, Martina$$b15
000302169 7001_ $$aRaimondi, Alessandra$$b16
000302169 7001_ $$aMarandino, Laura$$b17
000302169 7001_ $$aCinieri, Saverio$$b18
000302169 7001_ $$aIannelli, Elisabetta$$b19
000302169 7001_ $$aRipamonti, Carla Ida$$b20
000302169 7001_ $$aBossi, Paolo$$b21
000302169 7001_ $$00000-0003-3253-2960$$aNumico, Gianmauro$$b22
000302169 7001_ $$aLatiano, Tiziana$$b23
000302169 7001_ $$aPinto, Carmine$$b24
000302169 7001_ $$aQuaglini, Silvana$$b25
000302169 7001_ $$aLocati, Laura$$b26
000302169 7001_ $$aGussoni, Gualberto$$b27
000302169 7001_ $$aMignone, Gianluca$$b28
000302169 7001_ $$0P:(DE-He78)220ae95e502090f81d486cc30b17836d$$aCarrera, Pricivel$$b29
000302169 7001_ $$aBasch, Ethan$$b30
000302169 7001_ $$00000-0001-8906-3785$$aDi Maio, Massimo$$b31
000302169 7001_ $$aPerrone, Francesco$$b32
000302169 773__ $$0PERI:(DE-600)3166334-5$$a10.1136/bmjonc-2025-000783$$gVol. 4, no. 1, p. e000783 -$$n1$$pe000783$$tBMJ Oncology$$v4$$x2752-7948$$y2025
000302169 909CO $$ooai:inrepo02.dkfz.de:302169$$pVDB
000302169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)220ae95e502090f81d486cc30b17836d$$aDeutsches Krebsforschungszentrum$$b29$$kDKFZ
000302169 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000302169 9141_ $$y2025
000302169 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000302169 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000302169 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-11-09T09:28:07Z
000302169 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-11-09T09:28:07Z
000302169 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-11-09T09:28:07Z
000302169 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000302169 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000302169 9201_ $$0I:(DE-He78)B210-20160331$$kB210$$lNWG Somatische Evolution und Früherkennung$$x0
000302169 980__ $$ajournal
000302169 980__ $$aVDB
000302169 980__ $$aI:(DE-He78)B210-20160331
000302169 980__ $$aUNRESTRICTED